1. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
- Author
-
Connor YD, Miao D, Lin DI, Hayne C, Howitt BE, Dalrymple JL, DeLeonardis KR, Hacker MR, Esselen KM, and Shea M
- Subjects
- Adult, Carcinoma, Small Cell pathology, Carcinoma, Small Cell therapy, Cell Differentiation physiology, Cohort Studies, DNA Helicases deficiency, Female, Humans, Hypercalcemia pathology, Hypercalcemia therapy, Middle Aged, Nuclear Proteins deficiency, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Prognosis, Retrospective Studies, Sarcoma pathology, Sarcoma therapy, Transcription Factors deficiency, Uterine Neoplasms pathology, Uterine Neoplasms therapy, Carcinoma, Small Cell genetics, DNA Helicases genetics, Germ-Line Mutation, Hypercalcemia genetics, Nuclear Proteins genetics, Ovarian Neoplasms genetics, Sarcoma genetics, Transcription Factors genetics, Uterine Neoplasms genetics
- Abstract
Objective: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) and SMARCA4-deficient undifferentiated uterine sarcoma (SMARCA4-DUS) are rare and aggressive tumors, primarily affecting pre- and perimenopausal women. Inactivating SMARCA4 mutations are thought to be the driving molecular events in the majority of these tumors. Here, we report the clinical course of a family with germline SMARCA4 mutation and compare large cohorts of these rare tumor types., Methods: We extracted clinico-pathological medical record data for the family with germline SMARCA4 mutation. Clinico-genomic data from SCCOHT and SMARCA4-DUS cohorts were retrospectively extracted from the archives of a large CLIA-certified reference molecular laboratory., Results: We identified a single family with an inherited germline SMARCA4 mutation, in which two different family members developed either SCCOHT or SMARCA4-DUS, both of whom died within one year of diagnosis, despite aggressive surgical, chemotherapy and immunotherapy treatment. Retrospective comparative analysis of large SCCOHT (n = 48) and SMARCA4-DUS (n = 17) cohorts revealed that SCCOHT patients were younger (median age: 28.5 vs. 49.0) and more likely to have germline SMARCA4 alterations (37.5% vs. 11.8%) than SMARCA4-DUS patients., Conclusions: Growing understanding of the role SMARCA4 plays in the pathogenesis of these rare cancers may inform recommended genetic testing and counseling in families with these tumor types., Competing Interests: Declaration of competing interest DIL is a full-time employee of Foundation Medicine, Inc, which is a whole subsidiary of Roche., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF